Aloysius M M, Takhar A, Robins A, Eremin O
Section of Surgery, University Hospital Nottingham, Queen's Medical Centre, Nottingham UK.
Surgeon. 2006 Aug;4(4):195-210. doi: 10.1016/s1479-666x(06)80061-2.
Gastrointestinal (GI) cancers make up a significant proportion of newly diagnosed malignant disease. The five-year survival for these GI cancers is poor. Anti-cancer host defences are thought to play a role in these cancers, albeit they are suboptimal. Novel immunotherapies are being introduced to treat such patients. This review describes basic cell biology of dendritic cells, as they are thoughtto play a key role in generating effective anti-tumour responses. Dendritic cell dysfunction in patients with various cancers is documented and immunotherapy using dendritic cells in a range of GI cancers is described and discussed
胃肠道（GI）癌症在新诊断出的恶性疾病中占很大比例。这些胃肠道癌症的五年生存率很低。抗癌宿主防御机制被认为在这些癌症中发挥作用，尽管其效果并不理想。新型免疫疗法正在被引入用于治疗此类患者。本综述描述了树突状细胞的基础细胞生物学，因为它们被认为在产生有效的抗肿瘤反应中起关键作用。记录了各种癌症患者中树突状细胞功能障碍的情况，并描述和讨论了在一系列胃肠道癌症中使用树突状细胞的免疫疗法。
